These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17354533)

  • 1. [New trends in asthma therapy: is there a place for biologicals in 2007?].
    Bart PA
    Rev Med Suisse; 2007 Jan; 3(94):103-6. PubMed ID: 17354533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targets for persistent airway inflammation in refractory asthma.
    Murphy P; Hillman T; Rajakulasingam K
    Biomed Pharmacother; 2010 Feb; 64(2):140-5. PubMed ID: 20074901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stratified medicine in selecting biologics for the treatment of severe asthma.
    Morjaria JB; Proiti M; Polosa R
    Curr Opin Allergy Clin Immunol; 2011 Feb; 11(1):58-63. PubMed ID: 21150434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
    Arnett HA; Viney JL
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
    Molloy ES; Langford CA; Clark TM; Gota CE; Hoffman GS
    Ann Rheum Dis; 2008 Nov; 67(11):1567-9. PubMed ID: 18677012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD; Turk F
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of GINA suggested drugs for the treatment of asthma on Health-Related Quality of Life: a GA(2)LEN review.
    Baiardini I; Braido F; Brandi S; Tarantini F; Bonini S; Bousquet PJ; Zuberbier T; Demoly P; Canonica GW
    Allergy; 2008 Aug; 63(8):1015-30. PubMed ID: 18691305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic targets for new therapy for corticosteroid refractory asthma.
    Ito K; Mercado N
    Expert Opin Ther Targets; 2009 Sep; 13(9):1053-67. PubMed ID: 19659447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor-alpha in severe corticosteroid-refractory asthma.
    Morjaria JB; Babu KS; Polosa R; Holgate ST
    Expert Rev Respir Med; 2007 Aug; 1(1):51-63. PubMed ID: 20477266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
    Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
    Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept for refractory asthma therapy.
    Antoniu SA
    Expert Opin Investig Drugs; 2006 Oct; 15(10):1279-81. PubMed ID: 16989602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of asthma control and its impact on optimal treatment strategy.
    Lundback B; Dahl R
    Allergy; 2007 Jun; 62(6):611-9. PubMed ID: 17508964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IgE in severe persistent allergic asthma.
    Fox H
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanisms, diagnosis, and management of severe asthma in adults.
    Holgate ST; Polosa R
    Lancet; 2006 Aug; 368(9537):780-93. PubMed ID: 16935689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel molecular therapy.
    Wildhaber JH
    Paediatr Respir Rev; 2006; 7 Suppl 1():S104-5. PubMed ID: 16798525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.